The phase III
CASTOR and POLLUX studies previously demonstrated benefit of daratumumab plus bortezomib and dexamethasone (DVd) or lenalidomide
and dexamethasone (DRd) vs standard-of-care (SoC) Vd or Rd regimen in relapsed
or refractory multiple myeloma (R/R MM). The latest efficacy and safety results
after 4 years of follow-up from CASTOR and POLLUX were presented at the
American Society of Hematology (ASH) 61st Meeting & Exposition 2019 held in
Orlando, Florida, US.
US researchers have developed an emergency department (ED)–based protocol that would help standardize the assessment and treatment of von Willebrand disease (VWD) in adolescent females with heavy menstrual bleeding (HMB).
The combination of venetoclax with bortezomib and dexamethasone (Bd) significantly improves response rates in patients with relapsed/refractory multiple myeloma (RRMM), although survival, according to updated results of the BELLINI* study presented at ASH 2019.
The addition of daratumumab (D) to a bortezomib, melphalan, and prednisone (VMP) regimen improved overall survival (OS) in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplantation (ASCT), results of the phase III ALCYONE trial showed.
Adding epoetin alfa (EA) to lenalidomide significantly helps achieve major erythroid response (MER) in patients with erythropoietin (Epo)-refractory, lower risk non-deletion 5q (non-del(5q)) myelodysplastic syndrome (MDS) compared with lenalidomide alone, according to the final results of the E2905* trial presented at ASH 2019.
Sutimlimab, a first-in-class selective inhibitor of the classical complement pathway (CP), yields rapid and sustained efficacy in patients with cold agglutinin disease (CAD), a rare autoimmune haemolytic anaemia currently with no approved treatment, according to the Cardinal* study presented at ASH 2019.
In acutely ill medical patients, asymptomatic proximal deep-vein thrombosis (ASxDVT), as assessed via compression ultrasonography, is associated with an elevated risk of all-cause mortality, according to a post hoc analysis of the MAGELLAN* trial presented at ASH 2019.
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019.
A combination therapy of ibrutinib + rituximab continues to yield superior survival benefits compared with standard chemoimmunotherapy for treatment-naïve patients aged ≤70 years with chronic lymphocytic leukaemia (CLL), according to data from extended follow-up of the large ECOG 1912 (E1912) trial presented at ASH 2019 Meeting.
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.